Healthcare >> CEO Interviews >> July 8, 2002

Paul Averback – Nymox Pharmaceutical Corporation (nymx)

DR. PAUL AVERBACK is the Founder, CEO and President of Nymox Pharmaceutical Corporation. He is the inventor of Nymox's spheron technologies and the co-inventor with other scientists of many of Nymox's proprietary technologies. Dr. Averback has a vast experience as a successful independent entrepreneur, scientific researcher, medical specialist, and front-line practitioner, and he has successfully negotiated several strategic research collaborations with large multinational pharmaceutical companies in the US, Europe and Japan. Dr. Averback has extensive firsthand knowledge of health care, with positions including emergency room physician, family physician, clinic administrator and university medical faculty member. In addition to many issued and pending patents, Dr. Averback has published prolifically in peer review literature on subjects including pharmaceuticals, Alzheimer's disease, diagnostics, oncology, cytology, neuroanatomy, neuropathology, geometrical probability, embryology, morphometry, congenital disease, vascular disease, and others, including a significant list of worldwide first discoveries in many fields. Dr. Averback (MD 1975) holds a Diploma of the American Board of Pathology with Special Competence in Neuropathology, was a Medical Research Council Postdoctoral Fellow at Cambridge University (1977-1980) and was on the Faculty of Medicine at McGill University (1980-1985). Profile
TWST: Would you start with an overview of the company?

Dr. Averback: Nymox is involved in some of the most exciting R&D

projects in the world. Nymox was incorporated in 1989 and went